Douglas J. Jolly, PhD,
Executive VP Research & Pharmaceutical Development,
Tocagen, Inc. –
Toca511 – A retroviral replicating vector encoding a prodrug activating gene and a potential therapeutic for recurrent primary brain cancer in clinical trials